Mice deficient for the CD40 ligand

doi:10.1016/1074-7613(94)90073-6

Immunity

Volume 1, Issue 5, August 1994, Pages 423-431

https://doi.org/10.1016/1074-7613(94)90073-6 Get rights and content

Abstract

To study the Potential roles of CD40L in immune responses, we generated CD40L-deficient mice by gene targeting. Similar to the effects of CD40L mutations in humans (hyper-IgM syndrome), CD40L-deficient mice have a decreased IgM response to thymus-dependent antigens, fail altogether to produce an antigen-specific IgG1 response following Immunization, yet respond normally to a T-Independent antigen, TNP-Ficoll. Moreover, these mice do not develop germinal centers in response to thymus-dependent antigens, suggesting an inability to develop memory B cell responses. Although CD40L-deficient mice have low levels of most circulating immunoglobulin isotypes, they do not exhibit the spontaneous hyper-IgM syndrome seen in humans, at least up to 12 weeks of age. In summary, our study confirms the important role of CD40-CD40L interactions in thymus-dependent humoral immune responses and germinal center formation.

References (22)

A. Aruffo et al.
The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome
Cell
(1993)
T. Kawabe et al.
The Immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation
Immunity
(1994)
K.R. Thomas et al.
Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells
Cell
(1987)
R.C. Allen et al.
CD40 ligand gene defects responsible for X-linked hyper-IgM sydrome
Science
(1993)
R.J. Armitage et al.
Molecular and biological characterization of a murine ligand for CD40
Nature
(1992)
J. Banchereau et al.
The CD40 antigen and its ligand
Annu. Rev. Immunol.
(1994)
M. Baniyash et al.
Inhibition of IgE binding to mast cells and basophils by monoclonal antibodies to murine IgE
Eur. J. Immunol.
(1984)
H.N. Claman et al.
Immunologic complementation between thymus and marrow cells: a model for the two-cell theory of immunocompetence
Transplant. Rev.
(1969)
J.P. Disanto et al.
CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM
Nature
(1993)
T.M. Foy et al.
In vivo CD40-gp39 interactions are essential for thymus-dependent immunity. II. Prolonged in vivo suppression of primary and secondary humoral immune responses by an antibody targeted to the CD40 ligand, gp39
J. Exp. Med.
(1993)

T.M. Foy et al.

gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory

J. Exp. Med.

(1994)

Cited by (696)

Adapting to the world: The determination and plasticity of T follicular helper cells
2022, Journal of Allergy and Clinical Immunology
Antibodies are crucial in host defenses as well as in allergic diseases. T follicular helper (T_FH) cells play essential roles in germinal center reactions by facilitating B-cell differentiation and immunoglobulin affinity maturation and isotype switching. Although T_FH cells have a unique gene transcription program and regulatory network, recently there has been increasing evidence of T_FH cell plasticity, with some T_FH cells expressing genes typically related to other types of effector T cells associated with different types of Ig subclasses and in the context of different pathogen infections and health conditions. Here, we review the plasticity of T_FH cells in various types of immune responses. We also point out the important implications of T_FH plasticity in understanding and treating human diseases, including allergy.
An efficient immunoassay for the B cell help function of SARS-CoV-2-specific memory CD4<sup>+</sup> T cells
2022, Cell Reports Methods
The B cell “help” function of CD4⁺ T cells is an important mechanism of adaptive immunity. Here, we describe improved antigen-specific T-B cocultures for quantitative measurement of T cell-dependent B cell responses, with as few as ∼90 T cells. Utilizing M. tuberculosis (Mtb), we show that early priming and activation of CD4⁺ T cells is important for productive interaction between T and B cells and that similar effects are achieved by supplementing cocultures with monocytes. We find that monocytes promote survivability of B cells via BAFF and stem cell growth factor (SCGF)/C-type lectin domain family 11 member A (CLEC11A), but this alone does not fully recapitulate the effects of monocyte supplementation. Importantly, we demonstrate improved activation and immunological output of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific memory CD4⁺ T-B cell cocultures with the inclusion of monocytes. This method may therefore provide a more sensitive assay to evaluate the B cell help quality of memory CD4⁺ T cells, for example, after vaccination or natural infection.
Development of Tbet- and CD11c-expressing B cells in a viral infection requires T follicular helper cells outside of germinal centers
2022, Immunity
Citation Excerpt :
These cytokines inducing Tbet+CD11c+ B cells could be secreted in vivo by T follicular helper (Tfh) and T helper 1 (Th1) cells (Miyauchi et al., 2016; Weinstein et al., 2018). Tfh cells orchestrate germinal center (GC) responses through delivery of cytokines and contact-dependent help such as CD40 ligand (CD40L) (Linterman et al., 2010; Weinstein et al., 2018; Xu et al., 1994; Zotos et al., 2010). Generation of Tbet+CD11c+ B cells is impaired in CD40L- or in SLAM-associated protein (SAP, encoded by Sh2d1a)-deficient mice (Manni et al., 2018; Russell Knode et al., 2017), both of which have defects in Tfh cell differentiation and GC formation (Qi et al., 2008; Xu et al., 1994), suggesting that Tbet+CD11c+ B cell development is Tfh cell and GC dependent (Karnell et al., 2017; Knox et al., 2019).
Tbet⁺CD11c⁺ B cells arise during type 1 pathogen challenge, aging, and autoimmunity in mice and humans. Here, we examined the developmental requirements of this B cell subset. In acute infection, T follicular helper (Tfh) cells, but not Th1 cells, drove Tbet⁺CD11c⁺ B cell generation through proximal delivery of help. Tbet⁺CD11c⁺ B cells developed prior to germinal center (GC) formation, exhibiting phenotypic and transcriptional profiles distinct from GC B cells. Fate tracking revealed that most Tbet⁺CD11c⁺ B cells developed independently of GC entry and cell-intrinsic Bcl6 expression. Tbet⁺CD11c⁺ and GC B cells exhibited minimal repertoire overlap, indicating distinct developmental pathways. As the infection resolved, Tbet⁺CD11c⁺ B cells localized to the marginal zone where splenic retention depended on integrins LFA-1 and VLA-4, forming a competitive memory subset that contributed to antibody production and secondary GC seeding upon rechallenge. Therefore, Tbet⁺CD11c⁺ B cells comprise a GC-independent memory subset capable of rapid and robust recall responses.
Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint
2021, Pharmacology and Therapeutics
The CD40 receptor and its ligand CD40L is one of the most critical molecular pairs of the stimulatory immune checkpoints. Both CD40 and CD40L have a membrane form and a soluble form generated by proteolytic cleavage or alternative splicing. CD40 and CD40L are widely expressed in various types of cells, among which B cells and myeloid cells constitutively express high levels of CD40, and T cells and platelets express high levels of CD40L upon activation. CD40L self-assembles into functional trimers which induce CD40 trimerization and downstream signaling. The canonical CD40/CD40L signaling is mediated by recruitment of TRAFs and NF-κB activation, which is supplemented by signal pathways such as PI3K/AKT, MAPKs and JAK3/STATs. CD40/CD40L immune checkpoint leads to activation of both innate and adaptive immune cells via two-way signaling. CD40/CD40L interaction also participates in regulating thrombosis, tissue inflammation, hematopoiesis and tumor cell fate. Because of its essential role in immune activation, CD40/CD40L interaction has been regarded as an attractive immunotherapy target. In recent years, significant advance has been made in CD40/CD40L-targeted therapy. Various types of agents, including agonistic/antagonistic monoclonal antibodies, cellular vaccines, adenoviral vectors and protein antagonist, have been developed and evaluated in early-stage clinical trials for treating malignancies, autoimmune diseases and allograft rejection. In general, these agents have demonstrated favorable safety and some of them show promising clinical efficacy. The mechanisms of benefits include immune cell activation and tumor cell lysis/apoptosis in malignancies, or immune cell inactivation in autoimmune diseases and allograft rejection. This review provides a comprehensive overview of the structure, processing, cellular expression pattern, signaling and effector function of CD40/CD40L checkpoint molecules. In addition, we summarize the progress, targeted diseases and outcomes of current ongoing and completed clinical trials of CD40/CD40L-targeted therapy.
Class Switch Recombination Defects: impact on B cell maturation and antibody responses
2021, Clinical Immunology
To assess how B cell phenotype analysis correlates with antigen responses in patients with class switch recombination defects (CSRD) we quantified memory B cells by flow-cytometry and immunized CSRD patients with the neoantigen bacteriophage phiX174 (phage).
CSRD patients showed uniformly absent or markedly reduced switched memory B cells (IgM⁻IgD⁻CD27⁺). CD40L patients had reduced CD27⁺ memory B cells (both non-switched and switched). In NEMO patients, results varied depending on the IKKγ gene variant. Three of four AID patients had normal percentages of CD27⁺ memory B cells while CD27⁺IgM⁻IgD⁻ switched memory B cells were markedly reduced in all AID patients. Antibody response to phage was remarkably decreased with lack of memory amplification and class-switching in immunized CD40L, UNG deficient, and NEMO patients.
Distinct B-cell phenotype pattern correlated with abnormal antibody responses to a T-cell dependent neoantigen, representing a powerful tool to identify CSRD patients.
First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody
2020, American Journal of Transplantation
Iscalimab is a fully human, CD40 pathway blocking, nondepleting monoclonal antibody being developed as an immunosuppressive agent. We describe a first-in-human, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of iscalimab in healthy subjects and rheumatoid arthritis patients. Healthy subjects (n = 56) received single doses of intravenous iscalimab (0.03, 0.1, 0.3, 1, or 3 mg/kg), or subcutaneous iscalimab (3 mg/kg), or placebo. Rheumatoid arthritis patients (n = 20) received single doses of intravenous iscalimab (10 or 30 mg/kg) or placebo. Iscalimab exhibited target-mediated drug disposition resulting in dose-dependent and nonlinear pharmacokinetics. Complete (≥90%) CD40 receptor occupancy on whole blood B cells was observed at plasma concentrations >0.3-0.4 µg/mL. In subjects receiving 3 mg/kg iscalimab, antibody responses to keyhole limpet hemocyanin were transiently suppressed. CD40 occupancy by iscalimab prevented ex vivo human rCD154-induced expression of CD69 on B cells in whole blood. All doses were generally safe and well tolerated, with no clinically relevant changes in any safety parameters, including no evidence of thromboembolic events. Iscalimab appears to be a promising blocker of the CD40-CD154 costimulatory pathway with potential use in transplantation and other autoimmune diseases.

View all citing articles on Scopus

View full text

Immunity

ArticleMice deficient for the CD40 ligand

Abstract

Cell

Immunity

Cell

CD40 ligand gene defects responsible for X-linked hyper-IgM sydrome

Science

Molecular and biological characterization of a murine ligand for CD40

Nature

The CD40 antigen and its ligand

Annu. Rev. Immunol.

Inhibition of IgE binding to mast cells and basophils by monoclonal antibodies to murine IgE

Eur. J. Immunol.

Immunologic complementation between thymus and marrow cells: a model for the two-cell theory of immunocompetence

Transplant. Rev.

CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM

Nature

In vivo CD40-gp39 interactions are essential for thymus-dependent immunity. II. Prolonged in vivo suppression of primary and secondary humoral immune responses by an antibody targeted to the CD40 ligand, gp39

J. Exp. Med.

gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory

J. Exp. Med.

Article
Mice deficient for the CD40 ligand